NextCure (NASDAQ:NXTC – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07), Zacks reports.
NextCure Stock Up 5.2 %
NASDAQ:NXTC opened at $0.75 on Friday. The company has a fifty day moving average of $0.78 and a 200-day moving average of $1.12. The firm has a market capitalization of $21.01 million, a P/E ratio of -0.36 and a beta of 0.71. NextCure has a twelve month low of $0.66 and a twelve month high of $2.57.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective (down previously from $4.00) on shares of NextCure in a research note on Friday.
NextCure Company Profile
NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.
Recommended Stories
- Five stocks we like better than NextCure
- How Can Investors Benefit From After-Hours Trading
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Stocks to Buy While Others Stay on the Sidelines
- The Most Important Warren Buffett Stock for Investors: His Own
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
